Biogen/BIIB

$223.32

0.6%
-
1D1W1MYTD1YMAX

About Biogen

Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. It also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. It commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.
Ticker
BIIB
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Christopher Viehbacher
Employees
7,570
Headquarters
Cambridge, United States

Biogen Metrics

BasicAdvanced
$32.46B
Market cap
27.99
P/E ratio
$7.98
EPS
-0.02
Beta
-
Dividend rate

What the Analysts think about Biogen

Analyst Ratings

Majority rating from 36 analysts.
Buy

Price Targets

Average projection from 30 analysts.
36.23% upside
High $500.00
Low $230.00
$223.32
Current price
$304.23
Average price target

Biogen Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
10.46% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$2.39B
-5.69%
Net income
$249.7M
-466.67%
Profit margin
10.46%
-488.85%

Biogen Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 3.75%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$3.40
$4.02
$4.36
$3.30
-
Expected
$3.28
$3.77
$3.97
$3.18
$3.48
Surprise
3.69%
6.75%
9.74%
3.75%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Biogen stock

Buy or sell Biogen stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing